Reuters
30 Jul 2026, 10:48 UTC · 1h ago
Cytokinetics wins UK approval, NICE backing for heart disease drug
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
30 Jul 2026, 10:48 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Britain's medicines regulator has approved Cytokinetics' drug for a rare heart condition. — Regulatory approval is a primary catalyst for biotech valuation by enabling commercialization.
+0.60The UK's cost-effectiveness watchdog recommended the drug for NHS reimbursement. — Reimbursement approval ensures a guaranteed payment path and reduces commercial risk in the UK market.
+0.50The drug's potential patient reach in the UK is approximately 6,600 people. — Provides a quantifiable estimate of the addressable market size for revenue projections.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company's drug received regulatory approval and a reimbursement recommendation for the UK market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
